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Abstract  Idiopathic  CD4  lymphocytopenia  is  a  very  rare  condition  resulting  in  an
immunodeﬁciency  disorder  that  may  or  may  not  result  in  opportunistic  infections.
Since  its  description  in  the  early  1990s,  the  reason  for  this  immune  deﬁciency  has
remained  unclear.  Its  association  with  viral  illnesses,  such  as  West  Nile  virus  infec-
tion,  has  yet  to  be  described.  We  report  a  26-year-old  patient  who  presented  with
fever,  ascending  paralysis,  and  progressive  weakness  of  the  upper  extremities.  To
our  knowledge,  this  is  the  ﬁrst  case  of  neuroinvasive  West  Nile  virus  occurring  in  the
context  of  a  diagnosis  of  idiopathic  CD4  lymphocytopenia.
©  2013  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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Idiopathic  CD4  lymphocytopenia  (ICL)  may  be
asymptomatic  and  diagnosed  incidentally  or  may
present with  a  variety  of  opportunistic  infections,
including some  neurologic  and  autoimmune  disor-
ders [1—3].  Likewise,  West  Nile  virus  (WNV)  may  be
asymptomatic,  present  with  a  mild  febrile  illness,
or present  in  a  neuroinvasive  form  with  encephali-
tis, meningitis,  and/or  paralysis  [4].
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http://dx.doi.org/10.1016/j.jiph.2013.09.003We  report  an  unusual  case  in  which  a  patient
ad both  of  these  conditions  concurrently.  She  pre-
ented with  a high  fever,  lower  extremity  paralysis,
nd ascending  progressive  weakness  of  the  upper
xtremities following  a period  of  generalized  weak-
ess and  malaise.
ase reporthis  patient  was  a 26-year-old  Hispanic  female  who
resented  with  a history  of  low-grade  fever  and
ild back  pain  associated  with  progressive  weak-
ess of  her  lower  extremities  and  mild  urinary
 Sciences. Published by Elsevier Ltd. All rights reserved.
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ncontinence.  The  patient  stated  that  her  symp-
oms  began  in  March.  She  lived  in  the  desert  climate
f southwest  New  Mexico,  and  there  were  sev-
ral cases  of  WNV  infection  reported  in  that  time
eriod  and  location.  She  did  not  recall  receiv-
ng a  mosquito  bite  but  frequently  spent  time  in
he yard.  Her  medical  history  included  generalized
alaise, gastroenteritis-type  symptoms,  and  inter-
ittent frontal  headache  with  a  vesicular  rash  over
er lower  back  that  was  treated  with  valacyclovir.
On admission,  her  temperature  was  103 ◦F,  her
lood  pressure  (BP)  was  110/78  mmHg,  and  her
ulse was  102  beats/min.
A physical  examination  was  unremarkable
xcept  for  grade  2/5  strength  in  the  lower  extrem-
ties, which  progressed  to  0/5  strength  over  the
rst 48  h  of  her  admission;  deep  tendon  reﬂexes
ere absent.  Sensation  was  mildly  impaired.  Her
pper extremity  strength  was  4/5  bilaterally  with
ormal  sensation.
On admission,  labs  showed  the  following:  white
lood cell  count,  5700  cells/mm3;  hemoglobin,
1 g/dL;  hematocrit,  34%;  and  platelet  count,
12,000 cells/mm3. Serology  for  WNV  IgG  was  pos-
tive using  an  enzyme-linked  immunosorbent  assay
EIA) (LabCorp,  Dallas,  Texas).  The  patient’s  periph-
ral antineutrophil  cytoplasmic  antibody  (pANCA)
iter was  >1:640,  and  her  antinuclear  antibody
ANA) titer  was  1:320  with  a  homogeneous  pattern.
n HIV  test  was  negative.  Serum  IgG,  IgA,  and  IgM
ere normal.
Cerebrospinal  ﬂuid  analysis  revealed  the  follow-
ng: glucose  at  25  mg/dL;  protein  at  140  mg/dL;  red
lood cells  (RBCs)  at  30  cells/mm3; and  white  blood
ells (WBCs)  at  1066  cells/mm3 with  69%  polymor-
honuclear and  31%  mononuclear  leukocytes.  The
bsolute  CD4+  lymphocyte  count  was  73  cells/mm3.
erebrospinal  ﬂuid  (CSF)  culture  was  negative.  A
SF cryptococcal  antigen  test  was  negative.  CSF
erpes simplex  virus  (HSV)  1  and  2  PCR  results  were
egative.  CSF  cytomegalovirus  (CMV)  PCR  was  neg-
tive. CSF  WNV  IgM  and  IgG  were  positive  by  EIA
LabCorp, Dallas,  TX).
Brain  magnetic  resonance  imaging  (MRI)
evealed demyelination  and  an  expansile  appear-
nce of  the  spinal  cord.  MRI  of  the  spinal  cord
evealed marked  cord  expansion  with  hyperin-
ense signals  from  approximately  C2  through
1, suggesting  diffuse  myelitis.  Abdominal
ltrasound  and  computed  tomography  (CT)
evealed splenomegaly  and  bilateral  external
liac chain  lymphadenopathy,  which  was  clinically
nremarkable.
She was  started  empirically  on  plasmaphere-
is and  high-dose  intravenous  steroid  therapy
ith a  presumptive  diagnosis  of  a  Guillain—Barre
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yndrome-like  presentation  versus  transverse
yelitis. She  was  also  started  on  IV  valacyclovir
ntil the  CSF  HSV  PCR  results  were  available.
hen the  results  were  reported  as  negative,  the
alacyclovir  was  discontinued.  The  rash  resolved
n its  own.
Despite  the  plasmapheresis,  steroids,  and  intra-
enous  valacyclovir,  she  made  very  little  progress
n terms  of  improvement  in  strength.  The  use  of
V immunoglobulin  was  not  deemed  useful  in  this
ituation  and  was  therefore  not  used.  The  repeat
D4 count  performed  7  weeks  after  admission  was
8 cells/mm3. Serum  WNV  IgG  remained  elevated
y EIA  (LabCorp,  Dallas,  TX).
Based on  these  ﬁndings,  a  presumptive  diagnosis
as made  of  ICL  complicated  by  neuroinvasive  WNV
isease.
iscussion
CL  was  ﬁrst  described  in  1992  by  the  Centers  for
isease Control  and  Prevention  (CDC)  as  a  deple-
ion of CD4  T-lymphocytes  (absolute  count  <300/L
r <20%  of  total  lymphocytes)  at  a minimum  of  two
eparate time  points  at  least  6 weeks  apart,  with
o evidence  of  HIV  infection  and  an  absence  of
ny deﬁned  immunodeﬁciency  or  therapy  associ-
ted with  reduced  levels  of  CD4T  cells  [1,7]. ICL
s very  rare;  several  studies  have  been  performed
o identify  patients  with  ICL.  One  study  screened
028 blood  donors  and  did  not  identify  a single  case;
nother study  of  275  blood  donors,  970  transfusion
ecipients, and  947  household  contacts  of  trans-
usion  recipients  identiﬁed  12  cases  (0.5%).  The
revalence  of  ICL  is  generally  accepted  to  be  <1%,
lthough  the  true  prevalence  may  be  slightly  higher
han the  reported  number,  as  the  condition  can  be
symptomatic  [1].
The depletion  of  CD4  T-lymphocytes  in  ICL  may
o unnoticed,  but  ICL  patients  are  predisposed  to  a
ariety of  diseases  due  to  their  immunodeﬁciency.
he clinical  picture  of  ICL  regarding  opportunistic
nfections closely  parallels  HIV  due  to  the  sim-
lar nature  of  the  diseases.  Common  infections
ssociated with  ICL  include  cryptococcosis,  toxo-
lasmosis,  histoplasmosis,  and  non-tuberculosis
ycobacterial  infections  [6,8]. Other  associated
nfections include  herpes  zoster  (as  observed  in  our
atient), Kaposi’s  sarcoma,  human  papillomavirus,
pstein—Barr virus,  cytomegalovirus,  and  candidi-
sis [1,3,7].  Many  cases  of  progressive  multifocal
eukoencephalopathy  have  also  been  reported  in
ssociation  with  ICL  [2,9,10]  in  addition  to  an
ncreased  incidence  of  autoimmune  diseases  [3,6]
Table  1).
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Table  1  Opportunistic  infections  associated  with
idiopathic  CD4  lymphocytopenia  [7,  CDC].
Class  Infectious  agent
Bacteria
Fusobacterium  nucleatum
Mycobacterium  avium  intracellulare
Mycobacterium  mucogenicum
Mycobacterium  tuberculosis
Nocardia  spp
Salmonella  typhimurium
Viruses
Cytomegalovirus
Herpes  simplex  virus
Human  herpes  virus-8
Human  papillomavirus
JC  virus
Varicella  zoster  virus
Fungi
Aspergillus  spp
Candida  albicans
Cryptococcus  neoformans
Histoplasma  capsulatum
Pneumocystis  jirovecii
Leishmania  spp
Table  2  Clinical  syndromes  associated  with  WNV
infection,  CDC  2011.
Presentation  No.  of  cases  %  of  Total
Non-neuroinvasive  226  32
Neuroinvasive
Meningitis  183  26
Encephalitis  273  38
Acute  ﬂaccid  paralysis 30  4
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Treatment  for  ICL  varies  depending  on  the  pre-
sentation.  Patients  presenting  with  opportunistic
infections should  undergo  therapy  for  the  speciﬁc
condition with  which  they  present.  Asymptomatic
cases that  are  discovered  incidentally  should  be
monitored  regularly  to  evaluate  CD4  lymphocyte
counts and  to  watch  for  the  development  of  oppor-
tunistic  infections,  which  are  most  likely  to  develop
in the  ﬁrst  few  months  after  the  initial  presen-
tation. Experimental  cytokine  therapy,  such  as
synthetic  IL-2  and  IL-7  treatments,  has  had  a  vary-
ing degree  of  success  in  increasing  CD4  lymphocyte
counts, although  speciﬁc  therapy  is  difﬁcult  due
to the  unclear  mechanism  of  ICL  [3].  A  hand-
ful of  cases  have  reportedly  been  treated  with
allopathic bone  marrow  transplantation,  also  with
varying success  [13].  Several  studies  have  reported
the recovery  of  CD4  lymphocyte  counts  to  normal
limits, whereas  other  studies  have  not  shown  sig-
niﬁcant effects.  There  are  a  very  small  number  of
reported attempts  to  treat  ICL  with  bone  marrow
transplantation, which  is  generally  used  as  a last
resort for  extreme  cases;  its  clinical  utility  is  not
yet established  [13].  We  were  unable  to  conﬁrm
whether ICL  preceded  WNV  infection  in  our  patient
or began  afterward.
WNV was  ﬁrst  reported  in  New  York  in  1999.
More recently,  Texas  was  the  primary  site  of  an
outbreak of  the  disease  in  2012  [11].  According
to data  gathered  by  the  CDC  in  2011,  the  median
age of  WNV  patients  was  57  years  (range  7—96
s
c
fTotal 712  100
ears),  and  60%  of  patients  were  male.  Moreover,
3% of  the  cases  in  that  year  occurred  between
uly and  September,  with  a  peak  onset  in  late
ugust.
In our  patient’s  hometown  in  the  southwestern
SA, we  have  observed  several  cases  of  docu-
ented WNV  disease  with  a  variety  of  presentations
anging from  asymptomatic  to  simple  headaches  to
accid paralysis.  The  method  used  here  to  make
he diagnosis  included  the  clinical  presentation,  the
urrent epidemiology,  and  EIA  for  serological  and
SF analyses.
According  to  the  reference  laboratory  (LabCorp,
allas), the  EIA  test  is  95%  accurate  when  one  con-
iders the  clinical  presentation  and  the  concurrent
pidemiology and  season  in  which  the  case  pre-
ented. The  case  would  have  been  more  convincing
f we  had  been  able  to  obtain  WNV  CSF  PCR  results,
ut this  information  was  not  available  to  us.
The CDC  reported  712  cases  of  WNV  in  2011.
f those  712  cases,  486  (68%)  were  neuroinva-
ive; of  those  486  cases,  30  (6%)  had  acute  ﬂaccid
aralysis.  Some  cases  of  paralysis  did  not  develop
ntil 3—7  months  after  WNV  infection  [5],  which
s consistent  with  the  presentation  of  our  patient,
lthough the  onset  of  paralysis  can  also  occur
ithin hours  of  presentation  in  some  cases  [12].
NV infection  may  present  with  concurrent  autoim-
une disorders,  and  the  possible  delayed  onset  of
aralysis following  initial  infection  may  be  due  to
n immune-mediated  neuropathic  process  [4].  Our
atient appears  to  follow  the  pattern  described
n the  literature  with  delayed  paralysis  and  with
CL being  the  predisposing  cause  for  the  infection
Table  2).
Neuroinvasive  WNV  with  a  background  of  immu-
odeﬁciency is  very  uncommon.  According  to  a
eport from  April  2013,  there  have  been  ﬁve
eported cases  of neuroinvasive  WNV  disease  in  HIV-
nfected patients  in  the  USA.  Of  these  ﬁve  patients,
wo recovered  with  complete  resolution  of  their
ymptoms,  and  one  patient’s  disease  was  compli-
ated by  pneumonia  that  progressed  to  respiratory
ailure and  subsequent  death;  the  outcomes  of  the
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[diopathic  CD4  lymphopenia  associated  with  neuroi
nal  two  patients  were  unknown  [11].  No  record
f neuroinvasive  WNV  with  a  background  of  ICL  was
dentiﬁed.  Our  patient’s  neuroinvasive  WNV  disease
ppears  to  have  been  precipitated  by  the  immuno-
eﬁciency (although  we  cannot  be  absolutely  sure
f this  possibility)  or  might  have  been  an  unusual
resentation of  both  diseases  occurring  simulta-
eously [5,6].
In  summary,  our  case  demonstrates  a  possible
resentation of  ICL  concurrent  with  neuroinva-
ive WNV  infection  when  considering  the  clinical
resentation, the  season  in  which  it  occurred,
nd serological  ﬁndings.  This  case  demonstrates
everal interesting  points.  (1)  Clinical  transverse
yelitis may  be  a  presenting  feature  of  neuroin-
asive WNV  infection.  (2)  This  case  suggests  the
mportance  of  an  underlying  immune  deﬁciency
yndrome in  patients  presenting  with  atypical
eurological infections  that  are  severe  and  pro-
ressive.  (3)  Although  not  therapeutically  useful
t this  time,  early  diagnosis  is  beneﬁcial  in  pre-
icting prognosis  and  long-term  morbidity.  (4)  If
atients present  with  neurological  syndromes  asso-
iated with  serology  that  may  be  positive  for  other
utoimmune  disorders,  physicians  should  consider
CL with  or  without  WNV  disease.  (5)  The  use
f WNV  PCR  on  serum  and  CSF  samples  would
lso help  to  conﬁrm  these  cases.  Further  studies
re warranted  to  clarify  the  etiology  of  ICL  and
he clinical  syndrome  associated  with  WNV  infec-
ion.onﬂict of interest
here  were  no  conﬂicts  on  interest  during  the  writ-
ng of  this  paper.
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